ARTICLE | Company News
VimRx, Baxter deal
December 8, 2008 8:00 AM UTC
The companies signed a letter of intent to form a joint venture in ex vivo cell and gene therapy that will combine the assets of Baxter's Immunotherapy Division (Irvine, Calif.), including the Isolex 300 magnetic-cell separation system, with VMRX's genomics technology. ...